What is the best medication for an adult patient with major depressive disorder who has no known contraindications?

Best Medication for Depression

For an adult with major depressive disorder and no contraindications, select a second-generation antidepressant (SSRI or SNRI) as initial pharmacologic treatment, with the specific choice based on side effect profile, patient symptoms, and comorbidities rather than efficacy differences. 1

Key Evidence on Medication Selection

All second-generation antidepressants demonstrate equal efficacy for treatment-naive patients 2. The critical distinction lies in their adverse effect profiles, not their effectiveness at treating depression. This means your medication choice should prioritize tolerability and patient-specific factors.

Recommended First-Line Agents

SSRIs remain the standard starting point due to:

• Lower discontinuation rates (NNH 20-90) compared to older tricyclics (NNH 4-30) 2
• Established safety profile
• Once-daily dosing for most agents
• Lower toxicity in overdose 2

Tailoring Selection to Patient Characteristics

For working-age adults with fatigue or cognitive symptoms:

• Consider SNRIs (venlafaxine, duloxetine) or bupropion, which may provide broader symptom coverage 2
• Caveat: SNRIs have slightly higher discontinuation rates due to nausea/vomiting compared to SSRIs 2

For patients concerned about sexual dysfunction:

• Bupropion is preferred - associated with significantly lower rates of sexual adverse effects than fluoxetine and sertraline 1
• Avoid paroxetine, which has the highest rates of sexual dysfunction among SSRIs 1

For older adults (≥65 years):

• Preferred agents: citalopram, escitalopram, sertraline, mirtazapine, venlafaxine, or bupropion 2
• Avoid: paroxetine and fluoxetine due to higher adverse effect rates in this population 2

For patients on multiple medications:

• Consider desvenlafaxine or other agents with minimal drug-drug interactions 3

Critical Treatment Principles

Severity Matters

Antidepressants demonstrate greatest benefit in severe depression (Level A evidence) 2. For mild depression, consider cognitive behavioral therapy as monotherapy instead 4, 5.

Treatment Duration

• Minimum 4 months for first episode 2
• Longer duration for recurrent depression 2
• Adequate trial = 6-12 weeks at therapeutic dose before declaring treatment failure

Common Pitfalls to Avoid

1. Underdosing or inadequate trial duration - Most treatment "failures" reflect insufficient dosing or premature discontinuation

2. Ignoring side effect profiles - 63% of patients experience at least one adverse effect 2. Proactive discussion prevents discontinuation.

3. Not screening for bipolar disorder - Must rule out before initiating antidepressants to avoid precipitating mania 6

4. Overlooking functional outcomes - Target full remission and functional recovery, not just symptom reduction 6

Specific Adverse Effects to Discuss

Most common reasons for discontinuation:

• Nausea and vomiting (especially SNRIs) 2
• Sexual dysfunction (all except bupropion) 1
• Weight gain (varies by agent)
• Insomnia or sedation (agent-specific)

Serious but rare concerns:

• Serotonin syndrome (14-16% of SSRI overdoses) 2
• Increased suicidality monitoring (especially first 4-8 weeks)
• Hyponatremia (particularly in older adults)

When Initial Treatment Fails

Approximately 50-70% will not achieve remission with first antidepressant 7, 5. Second-step options include:

• Switching to different antidepressant class
• Augmentation with second medication
• Adding cognitive behavioral therapy 4, 5

Evidence shows similar efficacy among switching and augmentation strategies - choice depends on partial response versus no response and tolerability 7, 5.

Bottom Line Algorithm

1. Confirm diagnosis (rule out bipolar disorder, assess severity)
2. For moderate-severe MDD: Start SSRI (or SNRI/bupropion based on symptom profile)
3. Match medication to patient: Consider age, comorbidities, concomitant medications, specific symptoms
4. Discuss adverse effects upfront - particularly sexual dysfunction, GI effects, weight
5. Ensure adequate trial: Therapeutic dose for 6-12 weeks
6. If inadequate response: Switch class or augment (not just increase dose indefinitely)

The 2023 ACP guidelines 4, 5 and 2024 CANMAT update 8 both emphasize that cognitive behavioral therapy shows equivalent efficacy to antidepressants and should be offered as an alternative or adjunct, particularly for patients preferring non-pharmacologic approaches or those with mild depression.